You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

List of Excipients in API diltiazem hydrochloride extended release


✉ Email this page to a colleague

« Back to Dashboard


Excipients in NDA-approved (novel) drugs containing diltiazem hydrochloride extended release

Glossary
Company Tradename Ingredient NDC Excipient Potential Generic Entry
direct rx DILTIAZEM HYDROCHLORIDE EXTENDED RELEASE diltiazem hydrochloride extended release 72189-248 CELLULOSE, MICROCRYSTALLINE
direct rx DILTIAZEM HYDROCHLORIDE EXTENDED RELEASE diltiazem hydrochloride extended release 72189-248 D&C RED NO. 28
direct rx DILTIAZEM HYDROCHLORIDE EXTENDED RELEASE diltiazem hydrochloride extended release 72189-248 ETHYL ACRYLATE AND METHYL METHACRYLATE COPOLYMER
direct rx DILTIAZEM HYDROCHLORIDE EXTENDED RELEASE diltiazem hydrochloride extended release 72189-248 FD&C BLUE NO. 1
direct rx DILTIAZEM HYDROCHLORIDE EXTENDED RELEASE diltiazem hydrochloride extended release 72189-248 FD&C GREEN NO. 3
>Company >Tradename >Ingredient >NDC >Excipient >Potential Generic Entry

Subscribe to access the full database, or Sign Up

Detailed excipient profiles for diltiazem hydrochloride extended release

Excipient focus: CELLULOSE, MICROCRYSTALLINE

Excipient focus: D&C RED NO. 28

Excipient focus: ETHYL ACRYLATE AND METHYL METHACRYLATE COPOLYMER

Excipient focus: FD&C BLUE NO. 1

Excipient focus: FD&C GREEN NO. 3

Excipient focus: FD&C RED NO. 40

Excipient focus: FERROSOFERRIC OXIDE

Excipient focus: GELATIN

Excipient focus: HYPROMELLOSES

Excipient focus: MAGNESIUM STEARATE

Excipient focus: POLYSORBATE 80

Excipient focus: POVIDONE

Excipient focus: SUCROSE STEARATE

Excipient focus: TALC

Excipient focus: TITANIUM DIOXIDE

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

 
© Copyright 2002-2024 thinkBiotech LLC
ISSN: 2162-2639
Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2024 - 2025
 NCE-1 Patent Challenge Dates 2024 - 2025
 Trigger-based marketing for the life sciences
 Get DrugPatentWatch Business Intelligence Reports at Amazon.com
 DrugChatter - AI-based answers to questions about drugs
 RxJam - Digital Marketing for Life Sciences
Preferred Citation:

Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
   See Primary Research Papers Citing DrugPatentWatch

Links

Follow DrugPatentWatch:

  DrugPatentWatch Linkedin Group